Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BAY 3713372 in MTAP-deleted solid tumors
jRCT2031250514Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BAY 3713372 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC) (8 cohorts), sponsored by Bayer. Primary endpoints: Number of participants with treatment emergent adverse events, Number of participants with treatment emergent serious adverse events and 6 more. Started Dec 2025; status: recruiting.
02
Drugs
BAY 3713372
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031250514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250514.